<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766348</url>
  </required_header>
  <id_info>
    <org_study_id>HYK-DC-CTL-NSCLC</org_study_id>
    <nct_id>NCT02766348</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients</brief_title>
  <official_title>Randomized, Controlled Study of the Safety and Efficacy of DC-CTL Immune Cell for Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Hornetcorn Bio-technology Company, LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Hornetcorn Bio-technology Company, LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will
      receive only chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients with stage III-IV NSCLC will be randomly divided into group A (receive DC-CTL
      treatment with chemotherapy) or group B (Just receive chemotherapy), and the randomize ratio
      will be 1:1, patients in group A will receive 3 cycles of DC-CTL treatment (every 1 months)
      and 4 cycles of chemotherapy (every 2 weeks). Patients in group B will receive only 4 cycles
      chemotherapy(every 2 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>DC-CTL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks</description>
    <arm_group_label>DC-CTL</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-CTL</intervention_name>
    <description>8Ã—10^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32</description>
    <arm_group_label>DC-CTL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatinum</intervention_name>
    <description>cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.</description>
    <arm_group_label>DC-CTL</arm_group_label>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient who have signed the informed consent;

          -  Histologically confirmed with NSCLC at stage III-IV

          -  Expected survival time is more than 2 month;

          -  Eastern Cooperative Oncology Group(ECOG) performance status was 0-2

        Exclusion Criteria:

          -  Hemoglobin &lt;8.0 g/dL, White blood cell &lt;3 x 10^9/L; Platelet count &lt;75 x 10^9/L;
             alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea
             nitrogen(BUN) and Creatinine(CR) more than normal limits on 3.0 times;

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial;

          -  Pregnant or lactating patients;

          -  Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or
             TreponemaPallidun (TP) infection;

          -  Patients who are suffering from serious autoimmune disease;

          -  Patients who had used long time or are using immunosuppressant;

          -  Patients who had active infection;

          -  Patients who are suffering from serious organ dysfunction;

          -  Patients who are suffering from other cancer;

          -  Other situations that the researchers considered unsuitable for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zi L Zhang, researcher</last_name>
    <role>Study Director</role>
    <affiliation>Jingzhou Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zi L Zhang, researcher</last_name>
    <phone>18107168013</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Jingzhou Central hospital Immunotherapy center</name>
      <address>
        <city>Jingzhou</city>
        <state>Hubei</state>
        <zip>434020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fan Fu, Researcher</last_name>
      <phone>+86 15027082046</phone>
      <email>Fufan@hornetcorn.com</email>
    </contact>
    <contact_backup>
      <last_name>Fan Fu</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>May 6, 2016</last_update_submitted>
  <last_update_submitted_qc>May 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DC-CTL, NSCLC</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

